Rimegepant for the treatment of migraine
Migraine is a common form of primary headache, affecting up to 1 in every 6 Americans. The pathophysiology is an intricate interplay of genetic factors and environmental influence and is still being elucidated in ongoing studies. The trigeminovascular system is now known to have a significant role in the initiation of migraines, including the release of pain mediators such as CGRP and substance P. Traditional treatment of migraine is usually divided into acute and preventive treatment. Acute therapy includes non-specific therapy, such as NSAIDs and other analgesics, which may provide relief in mild to moderate migraines. 5-HT1 agonists may provide relief in severe migraine, but are not universally effective and carry a significant side-effect profile with frequent redosing requirement. Prophylactic therapy may reduce the occurrence of acute migraine attacks in selected patients, but does not completely eliminate it. More recently, CGRP antagonism has been studied and shown to be effective in both abortion and prevention of migraine. Novel medications, targeting CGRP, divide into CGRP antibodies and receptor antagonists (gepants). Rimegepant, a second-generation gepant, has shown efficacy in several clinical trials in treating acute migraine. Ongoing trials are also evaluating its role in migraine prophylaxis, and results are promising. It is also generally safer for use than existing options, does not appear to increase the chance of developing chronic migraines, and carries a very tolerable side effects profile. It is a part of a growing arsenal in migraine treatment, and may present the silver bullet for treatment of this disease.
1. Munjal S, Singh P, Reed ML, et al. Most Bothersome Symptom in Persons With Migraine: Results From the Migraine in America Symptoms and Treatment (MAST) Study. Headache. 2020;60(2):416-429. doi:10.1111/head.13708
2. Goadsby PJ. Pathophysiology of migraine. Ann Indian Acad Neurol. 2012;15(SUPPL.):15-22.
3. Natoli JL, Manack A, Dean B, et al. Global prevalence of chronic migraine: A systematic review. Cephalalgia. 2010;30(5):599-609. doi:10.1111/j.1468-2982.2009.01941.x
4. Rasmussen BK, Olesen J. Migraine with aura and migraine without aura: An epidemiological study. Cephalalgia. 1992;12(4):221-228. doi:10.1046/j.1468-2982.1992.1204221.x
5. Steiner TJ, Stovner LJ, Vos T. GBD 2015: migraine is the third cause of disability in under 50s. J Headache Pain. 2016;17(1):0-3. doi:10.1186/s10194-016-0699-5
6. Burch R, Rizzoli P, Loder E. The Prevalence and Impact of Migraine and Severe Headache in the United States: Figures and Trends From Government Health Studies. Headache. 2018;58(4):496-505. doi:10.1111/head.13281
7. Raval AD, Shah A. National Trends in Direct Health Care Expenditures Among US Adults With Migraine: 2004 to 2013. J Pain. 2017;18(1):96-107. doi:10.1016/j.jpain.2016.10.005
8. Bohm PE, Stancampiano FF, Rozen TD. Migraine Headache: Updates and Future Developments. Mayo Clin Proc. 2018;93:1648-1653.
9. Tepper SJ. Anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: Update on a Previous Review After the American Headache Society 60th Scientific Meeting, San Francisco, June 2018. Headache. 2018;58:276-290. doi:10.1111/head.13417
10. Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;377(22):2113-2122. doi:10.1056/NEJMoa1709038
11. Mullin K, Kudrow D, Croop R, et al. Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy. Neurology. 2020;94(20):e2121-e2125. doi:10.1212/WNL.0000000000008944
12. Schwedt TJ. Chronic migraine. Br Med J. 2014;348:g1416.
13. Stewart WF, Ricci JA, Chee E, Morganstein D, Lipton RB. Lost Productive Time and Cost Due to Common Pain Conditions in the US Workforce. JAMA. 2003;290(18):2443-2454. doi:10.1001/jama.290.18.2443
14. Stovner LJ, Andrée C. Impact of headache in Europe: A review for the Eurolight project. J Headache Pain. 2008;9(3):139-146. doi:10.1007/s10194-008-0038-6
15. Rizzoli P, Mullally WJ. Headache. Am J Med. 2018;131(1):17-24. doi:10.1016/j.amjmed.2017.09.005
16. Olesen J. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211.
17. Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB. Acute migraine medications and evolution from episodic to chronic migraine: A longitudinal population- based study. Headache. 2008;48(8):1157-1168. doi:10.1111/j.1526-4610.2008.01217.x
18. Buse DC, Manack A, Serrano D, Turkel C, Lipton RB. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry. 2010;81(4):428-432. doi:10.1136/jnnp.2009.192492
19. Puledda F, Messina R, Goadsby PJ. An update on migraine: current understanding and future directions. J Neurol. 2017;264(9):2031-2039. doi:10.1007/s00415-017-8434-y
20. Weiller C, May A, Limmroth V, et al. Brain stem activation in spontaneous human migraine attacks. Nat Med. 1995;1(July):658-660.
21. Charles A. The pathophysiology of migraine: implications for clinical management. Lancet Neurol. 2018;17(2):174-182. doi:10.1016/S1474-4422(17)30435-0
22. Moskowitz MA, Romero J, Reinhard JF Jr, Melamed E, Pettibone DJ. Neurotransmitters and the fifth cranial nerve: is there a relation to the headache phase of migraine? Lancet. 1979;314(8148):883-885. doi:10.1016/S0140-6736(79)92692-8
23. Ashina M, Hansen JM, Do TP, Melo-Carrillo A, Burstein R, Moskowitz MA. Migraine and the trigeminovascular system—40 years and counting. Lancet Neurol. 2019;18(8):795-804. doi:10.1016/S1474-4422(19)30185-1
24. Lennerz JK, Rühle V, Ceppa EP, et al. Calcitonin receptor-like receptor (CLR), receptor activity-modifying protein 1 (RAMP1), and calcitonin gene-related peptide (CGRP) immunoreactivity in the rat trigeminovascular system: Differences between peripheral and central CGRP receptor distribution. J Comp Neurol. 2008;507(3):1277-1299. doi:10.1002/cne.21607
25. Hansen JM, Ashina M. Calcitonin gene-related peptide and migraine with aura: A systematic review. Cephalalgia. 2014;34(9):695-707. doi:10.1177/0333102413520084
26. Hansen JM, Hauge AW, Olesen J, Ashina M. Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia. 2010;30(10):1179-1186. doi:10.1177/0333102410368444
27. Schulte LH, Jürgens TP, May A. Photo-, osmo- and phonophobia in the premonitory phase of migraine: mistaking symptoms for triggers? J Headache Pain. 2015;16(1):1-5. doi:10.1186/s10194-015-0495-7
28. Schulte LH, May A. The migraine generator revisited: Continuous scanning of the migraine cycle over 30 days and three spontaneous attacks. Brain. 2016;139(7):1987-1993. doi:10.1093/brain/aww097
29. Charles A. The evolution of a migraine attack - a review of recent evidence. Headache. 2013;53(2):413-419. doi:10.1111/head.12026
30. Burstein R, Noseda R, Borsook D. Migraine: multiple processes, complex pathophysiology. J Neurosci. 2015;35(17):6619-6629. doi:10.1523/JNEUROSCI.0373-15.2015
31. Baykan B, Ertas M, Karlı N, et al. Migraine incidence in 5 years: a population-based prospective longitudinal study in Turkey. J Headache Pain. 2015;16(1):1-10. doi:10.1186/s10194-015-0589-2
32. Bigal ME, Lipton RB. Modifiable Risk Factors for Migraine Progression. Headache. 2006;46(9):1334-1343. doi:10.1111/j.1526-4610.2006.00577.x
33. Scher AI, Midgette LA, Lipton RB. Risk factors for headache chronification. Headache. 2008;48(1):16-25. doi:10.1111/j.1526-4610.2007.00970.x
34. Scher AI, Stewart WF, Buse D, Krantz DS, Lipton RB. Major life changes before and after the onset of chronic daily headache: A population-based study. Cephalalgia. 2008;28(8):868-876. doi:10.1111/j.1468-2982.2008.01634.x
35. Louter MA, Bosker JE, Van Oosterhout WPJ, et al. Cutaneous allodynia as a predictor of migraine chronification. Brain. 2013;136(11):3489-3496. doi:10.1093/brain/awt251
36. Antonaci F, Ghiotto N, Wu S, Pucci E, Costa A. Recent advances in migraine therapy. Springerplus. 2016;5(1):1-14. doi:10.1186/s40064-016-2211-8
37. Peroutka SJ. What Turns on a Migraine? A Systematic Review of Migraine Precipitating Factors. Curr Pain Headache Rep. 2014;18(10):453-458. doi:10.1007/s11916-014-0454-z
38. Marmura MJ. Triggers, Protectors, and Predictors in Episodic Migraine. Curr Pain Headache Rep. 2018;22.
39. Holle D, Obermann M. The role of neuroimaging in the diagnosis of headache disorders. Ther Adv Neurol Disord. 2013;6(6):369-374. doi:10.1177/1756285613489765
40. Tsushima Y, Endo K. MR imaging in the evaluation of chronic or recurrent headache. Radiology. 2005;235(2):575-579. doi:10.1148/radiol.2352031210
41. Giffin NJ, Ruggiero L, Lipton RB, et al. Premonitory symptoms in migraine: An electronic diary study. Neurology. 2003;60(6):935-940. doi:10.1212/01.wnl.0000052998.58526.a9
42. Giffin NJ, Lipton RB, Silberstein SD, Olesen J, Goadsby PJ. GLOSSARY ICHD 5 International Classification of Headache Disorders. Neurology. 2016;87:309-313.
43. Quintela E, Castillo J, Muñoz P, Pascual J. Premonitory and Resolution Symptoms in Migraine: A Prospective Study in 100 Unselected Patients. Cephalalgia. 2006;26(9):1051-1060. doi:10.1111/j.1468-2982.2006.01157.x
44. Kelman L. The postdrome of the acute migraine attack. Cephalalgia. 2006;26(2):214-220. doi:10.1111/j.1468-2982.2005.01026.x
45. Gazerani P, Cairns BE. Sex-Specific Pharmacotherapy for Migraine: A Narrative Review. Front Neurosci. 2020;14:222. doi:10.3389/fnins.2020.00222
46. Goadsby PJ. Bench to bedside advances in the 21st century for primary headache disorders: Migraine treatments for migraine patients. Brain. 2016;139(10):2571-2577. doi:10.1093/brain/aww236
47. Diener HC, Charles A, Goadsby PJ, Holle D. New therapeutic approaches for the prevention and treatment of migraine. Lancet Neurol. 2015;14:1010-1022.
48. Society AH. The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice. Headache. 2019;59(1):1-18.
49. Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: The american headache society evidence assessment of migraine pharmacotherapies. Headache. 2015;55(1):3-20. doi:10.1111/head.12499
50. Hou M, Kanje M, Longmore J, Tajti J, Uddman R, Edvinsson L. 5-HT1B and 5-HT1D receptors in the human trigeminal ganglion: Co-localization with calcitonin gene-related peptide, substance P and nitric oxide synthase. Brain Res. 2001;909(1–2):112-120.
51. Cady RK, McAllister PJ, Spierings ELH, et al. A randomized, double-blind, placebo-controlled study of breath powered nasal delivery of sumatriptan powder (AVP-825) in the treatment of acute migraine (The TARGET Study). Headache. 2015;55(1):88-100. doi:10.1111/head.12472
52. Bird S, Derry S, Moore RA. Zolmitriptan for acute migraine attacks in adults. Cochrane Database Syst Rev. 2014;2017(5):CD008616. doi:10.1002/14651858.cd008616.pub2
53. Law S, Derry S, Moore RA. Sumatriptan plus naproxen for acute migraine attacks in adults. Cochrane database Syst Rev. 2013;2013(10):CD008541.
54. Tepper SJ, Cady RK, Silberstein S, et al. AVP-825 breath-powered intranasal delivery system containing 22 mg sumatriptan powder vs 100 mg oral sumatriptan in the acute treatment of migraines (The COMPASS study): a comparative randomized clinical trial across multiple attacks. Headache. 2015;55(5):621-635. doi:10.1111/head.12583
55. Lipton RB, Munjal S, Brand-Schieber E, Rapoport AM. DFN-02 (Sumatriptan 10 mg With a Permeation Enhancer) Nasal Spray vs Placebo in the Acute Treatment of Migraine: A Double-Blind, Placebo-Controlled Study. Headache. 2018;58(5):676-687. doi:10.1111/head.13309
56. Cameron C, Kelly S, Hsieh SC, et al. Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta-Analysis. Headache. 2015;55(S4):221-235.
57. Rapoport AM, Freitag F, Pearlman SH. Innovative delivery systems for migraine: the clinical utility of a transdermal patch for the acute treatment of migraine. CNS Drugs. 2010;24(11):929-940. doi:10.2165/11317540-000000000-00000
58. Ceriani CEJ, Wilhour DA, Silberstein SD. Novel Medications for the Treatment of Migraine. Headache. 2019;59(9):1597-1608. doi:10.1111/head.13661
59. de Vries T, Villalón CM, MaassenVanDenBrink A. Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans. Pharmacol Ther. 2020;211:107528.
60. Digre KB. What’s New in the Treatment of Migraine? J Neuro-Ophthalmology. 2019;39(3):352-359. doi:10.1097/wno.0000000000000837
61. Tfelt-Hansen PC. Does sumatriptan cross the blood-brain barrier in animals and man? J Headache Pain. 2010;11:5-12.
62. Mehta D, Leary MC, Yacoub HA, et al. The Effect of Regional Anesthetic Sphenopalatine Ganglion Block on Self-Reported Pain in Patients With Status Migrainosus. Headache. 2019;59(1):69-76. doi:10.1111/head.13390
63. Diamond S, Bigal ME, Silberstein S, Loder E, Reed M, Lipton RB. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: Results from the American migraine prevalence and prevention study. Headache. 2007;47(3):355-363.
64. Lipton RB, Serrano D, Nicholson RA, Buse DC, Runken MC, Reed ML. Impact of NSAID and Triptan Use on Developing Chronic Migraine: Results From the American Migraine Prevalence and Prevention (AMPP) Study. Headache. 2013;53(10):1548-1563. doi:10.1111/head.12201
65. Thorlund K, Toor K, Wu P, et al. Comparative tolerability of treatments for acute migraine: A network meta-analysis. Cephalalgia. 2017;37(10):965-978. doi:10.1177/0333102416660552
66. Dodick D, Lipton RB, Martin V, et al. Consensus statement: Cardiovascular safety profile of triptans (5-HT 1B/1D agonists) in the acute treatment of migraine. Headache. 2004;44(5):414-425. doi:10.1111/j.1526-4610.2004.04078.x
67. Do TP, Guo S, Ashina M. Therapeutic novelties in migraine: New drugs, new hope? J Headache Pain. 2019;20(1):1-13.
68. Ong JJY, Wei DYT, Goadsby PJ. Recent Advances in Pharmacotherapy for Migraine Prevention: From Pathophysiology to New Drugs. Drugs. 2018;78(4):411-437. doi:10.1007/s40265-018-0865-y
69. Aoki KR, Francis J. Updates on the antinociceptive mechanism hypothesis of botulinum toxin A. Park Relat Disord. 2011;17(SUPPL. 1):S28-33.
70. Mathew NT, Frishberg BM, Gawel M, et al. Botulinum toxin type a (Botox) for prophylactic treatment of chronic daily headache: A randomized, double-blind, placebo-controlled trial. Headache. 2005;45(4):293-307. doi:10.1111/j.1526-4610.2005.05066.x
71. Proietti Cecchini A, Grazzi L. Emerging therapies for chronic migraine. Curr Pain Headache Rep. 2014;18(4).
72. Sandrini G, Perrotta A, Tassorelli C, et al. Botulinum toxin type-A in the prophylactic treatment of medication-overuse headache: A multicenter, double-blind, randomized, placebo-controlled, parallel group study. J Headache Pain. 2011;12(4):427-433. doi:10.1007/s10194-011-0339-z
73. Ranoux D, Attal N, Morain F, Bouhassira D. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol. 2008;64(3):274-283. doi:10.1002/ana.21427
74. Herd CP, Tomlinson CL, Rick C, et al. Botulinum toxins for the prevention of migraine in adults. Cochrane Database of Systematic Reviews. 2018;2018.
75. Naegel S, Obermann M. Topiramate in the prevention and treatment of migraine: Efficacy, safety and patient preference. Neuropsychiatr Dis Treat. 2010;6(1):17-28.
76. Urits I, Clark G, An D, et al. An Evidence-Based Review of Fremanezumab for the Treatment of Migraine. Pain Ther. 2020;9(1):195-215. doi:10.1007/s40122-020-00159-3
77. White HS. Molecular pharmacology of topiramate: Managing seizures and preventing migraine. Headache. 2005;45(SUPPL. 1):48-56.
78. Raffaelli B, Reuter U. The Biology of Monoclonal Antibodies: Focus on Calcitonin Gene-Related Peptide for Prophylactic Migraine Therapy. Neurotherapeutics. 2018;15(2):324-335. doi:10.1007/s13311-018-0622-7
79. Yuan H, Spare NM, Silberstein SD. Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review. Headache. 2019;59(S2):20-32.
80. Paemeleire K, MaassenVanDenBrink A. Calcitonin-gene-related peptide pathway mAbs and migraine prevention. Curr Opin Neurol. 2018;31(3):274-280. doi:10.1097/WCO.0000000000000548
81. Russo AF. Calcitonin Gene-Related Peptide (CGRP): A New Target for Migraine. Annu Rev Pharmacol Toxicol. 2015;55(2):533-552. doi:10.1146/annurev-pharmtox-010814-124701
82. Deen M, Correnti E, Kamm K, et al. Blocking CGRP in migraine patients – a review of pros and cons. Journal of Headache and Pain. 2017;18.
83. Raffaelli B, Neeb L, Reuter U. Monoclonal antibodies for the prevention of migraine. Expert Opin Biol Ther. Published online 2019:1-11.
84. Reuter U, Goadsby PJ, Lanteri-Minet M, et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomized, double-blind, placebo-controlled, phase 3b study. Lancet. 2018;392(10161):2280-2287. doi:10.1016/s0140-6736(18)32534-0
85. Xu D, Chen D, Zhu L na, et al. Safety and tolerability of calcitonin-gene-related peptide binding monoclonal antibodies for the prevention of episodic migraine – a meta-analysis of randomized controlled trials. Cephalalgia. 2019;39(9):1164-1179. doi:10.1177/0333102419829007
86. Negro A, Martelletti P. Gepants for the treatment of migraine. Expert Opin Investig Drugs. 2019;28(6):555-567. doi:10.1080/13543784.2019.1618830
87. Bigal ME, Walter S, Rapoport AM. Therapeutic antibodies against CGRP or its receptor. Br J Clin Pharmacol. 2015;79(6):886-895. doi:10.1111/bcp.12591
88. Favoni V, Giani L, Al-Hassany L, et al. CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP? J Headache Pain. 2019;20(1):27. doi:10.1186/s10194-019-0979-y
89. Evans RW. Raynaud’s Phenomenon Associated With Calcitonin Gene-Related Peptide Monoclonal Antibody Antagonists. Headache. 2019;59(8):1360-1364. doi:10.1111/head.13596
90. Chan C, Goadsby PJ. Recent Advances in Pharmacotherapy for Episodic Migraine. CNS Drugs. 2019;33(11):1053-1071. doi:10.1007/s40263-019-00665-9
91. Scott LJ. Rimegepant: First Approval. Drugs. 2020;80(7):741-746. doi:10.1007/s40265-020-01301-3
92. Luo G, Chen L, Conway CM, et al. Discovery of (5S,6S,9R)-5-Amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate (BMS-927711): An Oral Calcitonin Gene-Related Peptide (CGRP) Antagonist in Clinical Trials for Treating Migraine. J Med Chem. 2012;55(23):10644-10651. doi:10.1021/jm3013147
93. Nurtec ODT [prescribing information]. New Haven, CT; 2020.
94. Mallick-Searle T, Moriarty M. Unmet needs in the acute treatment of migraine attacks and the emerging role of calcitonin gene–related peptide receptor antagonists. J Am Assoc Nurse Pract. 2020;1.
95. Biohaven Pharmaceuticals I. Dosing and Administration | NurtecTM ODT (rimegepant) 75 mg Orally Disintegrating Tablets.
96. De Matteis E, Guglielmetti M, Ornello R, Spuntarelli V, Martelletti P, Sacco S. Targeting CGRP for migraine treatment: mechanisms, antibodies, small molecules, perspectives. Expert Rev Neurother. Published online 2020:1-15.
97. Maasumi K, Michael RL, Rapoport AM. CGRP and Migraine: The Role of Blocking Calcitonin Gene-Related Peptide Ligand and Receptor in the Management of Migraine. Drugs. 2018;78(9):913-928. doi:10.1007/s40265-018-0923-5
98. Edvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new migraine therapies — successful translation from bench to clinic. Nat Rev Neurol. 2018;14(6):338-350. doi:10.1038/s41582-018-00003-1
99. Cernuda-Morollon E, Larrosa D, Ramon C, Vega J, Martinez-Camblor P, Pascual J. Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology. 2013;81(14):1191-1196. doi:10.1212/wnl.0b013e3182a6cb72
100. Urits I, Jones MR, Gress K, et al. CGRP Antagonists for the Treatment of Chronic Migraines: a Comprehensive Review. Current Pain and Headache Reports. 2019;23.
101. Pascual J. Efficacy of BMS-927711 and other gepants vs triptans: there seem to be other players besides CGRP. Cephalalgia. 2014;34(12):1028-1029. doi:10.1177/0333102414526052
102. Tepper SJ. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment. Headache. 2018;58(Suppl 3):238-275.
103. de Vries T, Villalón CM, MaassenVanDenBrink A. Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans. Pharmacol Ther. 2020;211.
104. Eftekhari S, Salvatore CA, Calamari A, Kane SA, Tajti J, Edvinsson L. Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion. Neuroscience. 2010;169(2):683-696. doi:10.1016/j.neuroscience.2010.05.016
105. Eftekhari S, Warfvinge K, Blixt FW, Edvinsson L. Differentiation of nerve fibers storing CGRP and CGRP receptors in the peripheral trigeminovascular system. J Pain. 2013;14(11):1289-1303. doi:10.1016/j.jpain.2013.03.010
106. Edvinsson L, Ekman R, Goadsby PJ. Measurement of vasoactive neuropeptides in biological materials: problems and pitfalls from 30 years of experience and novel future approaches. Cephalalgia. 2010;30(6):761-766. doi:10.1177/0333102409351807
107. Wattiez AS, Sowers LP, Russo AF. Calcitonin gene-related peptide (CGRP): role in migraine pathophysiology and therapeutic targeting. Expert Opin Ther Targets. 2020;24(2):91-100. doi:10.1080/14728222.2020.1724285
108. Iyengar S, Ossipov MH, Johnson KW. The role of calcitonin gene–related peptide in peripheral and central pain mechanisms including migraine. Pain. 2017;158(4):543-559. doi:10.1097/j.pain.0000000000000831
109. Hong P, Tan T, Liu Y, Xiao J. Gepants for abortive treatment of migraine: A network meta-analysis. Brain Behav. Published online 2020.
110. Sheykhzade M, Amandi N, Pla MV, et al. Binding and functional pharmacological characteristics of gepant-type antagonists in rat brain and mesenteric arteries. Vascul Pharmacol. 2017;90:36-43. doi:10.1016/j.vph.2017.02.001
111. Edvinsson L, Warfvinge K. Recognizing the role of CGRP and CGRP receptors in migraine and its treatment. Cephalalgia. 2019;39(3):366-373. doi:10.1177/0333102417736900
112. Eftekhari S, Salvatore CA, Johansson S, Chen TB, Zeng Z, Edvinsson L. Localization of CGRP, CGRP receptor, PACAP and glutamate in trigeminal ganglion. Relation to the blood–brain barrier. Brain Res. 2015;1600:93-109. doi:10.1016/j.brainres.2014.11.031
113. Dubowchik GM, Conway CM, Xin AW. Blocking the CGRP Pathway for Acute and Preventive Treatment of Migraine: The Evolution of Success. Journal of Medicinal Chemistry. Published online 2020.
114. Edvinsson L. Rimegepant oral disintegrating tablet for migraine. Lancet. 2019;394(10200):711-712. doi:10.1016/s0140-6736(19)31611-3
115. Marcus R, Goadsby PJ, Dodick D, Stock D, Manos G, Fischer TZ. BMS-927711 for the acute treatment of migraine: A double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia. 2014;34(2):114-125. doi:10.1177/0333102413500727
116. Pascual J. Efficacy of BMS-927711 and other gepants vs triptans: there seem to be other players besides CGRP. Cephalalgia. 2014;34(12):1028-1029. doi:10.1177/0333102414526052
117. Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019;394(10200):737-745. doi:10.1016/s0140-6736(19)31606-x
118. Croop R, Goadsby PJ, Stock DA, Lipton RB. Testing rimegepant for migraine—time to revise the trial design? – Authors’ reply. Lancet. 2020;395:1901-1902.
119. Gasparini S, Torino C, Branca D, Ferlazzo E, Aguglia U. Testing rimegepant for migraine—time to revise the trial design? Lancet. 2020;395(10241):1901. doi:10.1016/s0140-6736(20)30241-5
120. Ju C, Spiegel R, Radecki R, Swaminathan AK. Rimegepant in the Treatment of Migraine Headache: The Importance of Comparator Treatments: November 2019 Annals of Emergency Medicine Journal Club. Ann Emerg Med. 2019;74(5):721-723. doi:10.1016/j.annemergmed.2019.09.014
121. McCarthy L. Commentary. Annals of Internal Medicine. 2019;171:JC58-59.
122. Lipton RB, Croop R, Stock EG, et al. Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. N Engl J Med. 2019;381(2):142-149. doi:10.1056/nejmoa1811090
123. Gao B, Yang Y, Wang Z, et al. Efficacy and Safety of Rimegepant for the Acute Treatment of Migraine: Evidence From Randomized Controlled Trials. Front Pharmacol. 2019;10:1577. doi:10.3389/fphar.2019.01577
124. Tfelt-Hansen P, Loder E. The Emperor’s New Gepants: Are the Effects of the New Oral CGRP Antagonists Clinically Meaningful? Headache. 2019;59(1):113-117. doi:10.1111/head.13444
125. Mullin K, Kudrow D, Croop R, et al. Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy. Neurology. 2020;94(20):e2121-e2125. doi:10.1212/wnl.0000000000008944
126. Safety and Efficacy Study in Adult Subjects With Acute Migraines - Full Text View - ClinicalTrials.gov.
127. Efficacy and Safety Trial of Rimegepant for Migraine Prevention in Adults - Full Text View - ClinicalTrials.gov.
128. Trial for Treatment Refractory Trigeminal Neuralgia - Full Text View - ClinicalTrials.gov.
129. Edvinsson L. The Trigeminovascular Pathway: Role of CGRP and CGRP Receptors in Migraine. Headache. 2017;57(Suppl 2):47-55.
130. Edvinsson L. The CGRP Pathway in Migraine as a Viable Target for Therapies. Headache. 2018;58:33-47. doi:10.1111/head.13305